The role of HER2 status and targeted therapy with trastuzumab in advanced endometrial cancer, emphasizing the need for effective management of cardiac toxicities and comorbidities.
Camrelizumab Plus Famitinib Shows Promise in Recurrent or Metastatic Cervical Cancer
Naumann Discusses Notable Research Efforts in Endometrial Cancer
Retifanlimab Continues to Elicit Responses in Recurrent MSI-H or dMMR Endometrial Cancer
FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer
Recent Developments in Ovarian and Endometrial Cancers Stir Excitement Among Clinicians
Atezolizumab Plus Bevacizumab and Chemo Improves Survival in Metastatic or Recurrent Cervical Cancer
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations